BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:16 PM
 | 
Sep 09, 2008
 |  BC Extra  |  Top Story

Byetta v. Januvia data

Amylin (NASDAQ:AMLN) said Byetta exenatide met all primary and secondary endpoints of short-term clinical effects vs. Januvia sitagliptin from Merck (NYSE:MRK) in a Phase IV trial to treat Type II diabetes. Amylin said the results of the four-week, double-blind, crossover, head-to-head U.S. study in 61 evaluable patients showed that Byetta, a synthetic exendin-4,...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >